EP4263506C0 - SUBSTITUTED PIPERIDINE COMPOUNDS AND RELEVANT TREATMENT METHODS - Google Patents
SUBSTITUTED PIPERIDINE COMPOUNDS AND RELEVANT TREATMENT METHODSInfo
- Publication number
- EP4263506C0 EP4263506C0 EP21854780.0A EP21854780A EP4263506C0 EP 4263506 C0 EP4263506 C0 EP 4263506C0 EP 21854780 A EP21854780 A EP 21854780A EP 4263506 C0 EP4263506 C0 EP 4263506C0
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment methods
- piperidine compounds
- substituted piperidine
- relevant treatment
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128511P | 2020-12-21 | 2020-12-21 | |
| PCT/US2021/064484 WO2022140317A1 (en) | 2020-12-21 | 2021-12-21 | Substituted piperidino compounds and related methods of treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP4263506A1 EP4263506A1 (en) | 2023-10-25 |
| EP4263506B1 EP4263506B1 (en) | 2025-02-05 |
| EP4263506C0 true EP4263506C0 (en) | 2025-02-05 |
Family
ID=80218521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21854780.0A Active EP4263506B1 (en) | 2020-12-21 | 2021-12-21 | Substituted piperidino compounds and related methods of treatment |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11760747B2 (en) |
| EP (1) | EP4263506B1 (en) |
| JP (1) | JP2023554282A (en) |
| CN (1) | CN116670124A (en) |
| AU (1) | AU2021409664A1 (en) |
| CA (1) | CA3172862A1 (en) |
| ES (1) | ES3012114T3 (en) |
| WO (1) | WO2022140317A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023502441A (en) | 2019-11-25 | 2023-01-24 | アルカームス インコーポレーテッド | SUBSTITUTED MACROCYCLES AND RELATED THERAPEUTIC METHODS |
| CN117651703A (en) * | 2021-05-26 | 2024-03-05 | 阿尔克姆斯有限公司 | Substituted carbamic acid macrocyclic compounds and related methods of treatment |
| CN119730843A (en) * | 2022-06-21 | 2025-03-28 | 阿尔克姆斯有限公司 | Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment |
| WO2024141660A2 (en) | 2022-12-30 | 2024-07-04 | Aexon Labs. Inc. | Dihydro-quinazoline, -benzothiazine and -benzoxazine derivatives and use thereof as orexin receptors agonists for treating or preventing neurological diseases |
| WO2024246867A1 (en) * | 2023-06-02 | 2024-12-05 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for improving respiratory function during sleep |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8258163B2 (en) | 2008-06-04 | 2012-09-04 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| WO2012137982A2 (en) * | 2011-04-05 | 2012-10-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
| AU2013234499B2 (en) | 2012-03-17 | 2017-07-27 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| WO2014198880A1 (en) | 2013-06-14 | 2014-12-18 | Ferrer Internacional, S.A. | 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity |
| WO2015048091A1 (en) | 2013-09-24 | 2015-04-02 | The Board Of Regents Of The University Of Texas System | Orexin-control of bone formation and loss |
| CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
| KR20160105812A (en) | 2013-12-12 | 2016-09-07 | 고쿠리쯔 다이가쿠 호징 츠쿠바 다이가쿠 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| JP6552117B2 (en) | 2014-03-28 | 2019-07-31 | 国立大学法人 筑波大学 | Sepsis preventive and therapeutic agent |
| US9611262B2 (en) | 2014-09-11 | 2017-04-04 | Janssen Pharmaceutica Nv | Substituted 2-azabicycles and their use as orexin receptor modulators |
| WO2016133160A1 (en) | 2015-02-19 | 2016-08-25 | 国立大学法人筑波大学 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| JP6775803B2 (en) | 2015-06-12 | 2020-10-28 | 国立大学法人 筑波大学 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof |
| FI3984994T3 (en) | 2016-02-04 | 2024-10-03 | Takeda Pharmaceuticals Co | A SUBSTITUTED PIPERIDINE COMPOUND AS AN OREXIN TYPE 2 AGONIST FOR THE TREATMENT OF NARCOLEPSY |
| EP3594203B1 (en) | 2017-03-08 | 2021-08-04 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| WO2018164192A1 (en) | 2017-03-08 | 2018-09-13 | 武田薬品工業株式会社 | Substituted pyrrolidine compound and use thereof |
| US11319286B2 (en) | 2017-08-03 | 2022-05-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| CN111051295B (en) | 2017-08-03 | 2022-09-02 | 武田药品工业株式会社 | Heterocyclic compounds and their use |
| US11324724B2 (en) | 2017-09-28 | 2022-05-10 | Boehringer Ingelheim International Gmbh | N-(2,2-difluoroethyl)-N-[(pyrimidinylamino)propanyl]arylcarboxamides |
| BR112020019818A2 (en) | 2018-03-27 | 2021-01-05 | Board Of Regents, The University Of Texas System | OX2R COMPOUNDS |
| US12077522B2 (en) | 2018-06-29 | 2024-09-03 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| EP3816153B1 (en) | 2018-06-29 | 2023-10-18 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| JP7408569B2 (en) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | heterocyclic compound |
| WO2020122092A1 (en) | 2018-12-12 | 2020-06-18 | 武田薬品工業株式会社 | Heterocyclic compound |
| EA202192138A1 (en) | 2019-01-31 | 2022-03-10 | Такеда Фармасьютикал Компани Лимитед | HETEROCYCLIC COMPOUND AND ITS APPLICATIONS |
| EP3924058A1 (en) | 2019-02-13 | 2021-12-22 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| EP3923933A4 (en) | 2019-02-13 | 2022-08-17 | Merck Sharp & Dohme Corp. | PYRROLIDINOREXINE RECEPTOR AGONISTS |
| US12312332B2 (en) | 2019-08-08 | 2025-05-27 | Merck Sharp & Dohme Llc | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| WO2021048821A1 (en) | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for the treatment of excessive sleepiness |
| US11352357B2 (en) | 2019-11-27 | 2022-06-07 | Sumitomo Dainippon Pharma Co., Ltd. | Cycloalkylurea derivative |
| EP4066893A4 (en) | 2019-11-27 | 2023-12-20 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| BR112022013547A2 (en) | 2020-01-10 | 2022-09-06 | Takeda Pharmaceuticals Co | METHODS TO ENHANCE PHARMACOKINETICS, TO INCREASE PLASMATIC CONCENTRATION AND WAKENESS, OR TO REDUCE EXCESSIVE SLEEPING, AND, COMPOSITION |
| JP7190612B2 (en) | 2020-07-17 | 2022-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Substituted piperidine compound and use thereof |
| MX2023001840A (en) | 2020-08-18 | 2023-03-13 | Merck Sharp & Dohme Llc | Bicycloheptane pyrrolidine orexin receptor agonists. |
| EP4199925A4 (en) | 2020-08-18 | 2024-08-28 | Merck Sharp & Dohme LLC | Cyclopentapyrrole orexin receptor agonists |
| WO2022051583A1 (en) | 2020-09-03 | 2022-03-10 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists |
| EP4208444A1 (en) | 2020-09-03 | 2023-07-12 | Orexia Therapeutics Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| JP2022064180A (en) | 2020-10-13 | 2022-04-25 | 武田薬品工業株式会社 | Heterocyclic compound |
| AU2021368052A1 (en) | 2020-11-02 | 2023-06-08 | Merck Sharp & Dohme Llc | Macrocyclic urea orexin receptor agonists |
| WO2022109117A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | 3-amino pyrrolidine and piperidine macrocyclic orexin receptor agonists |
| EP4255429A4 (en) | 2020-12-03 | 2024-12-11 | Merck Sharp & Dohme LLC | 3-HETEROARYL PYRROLIDINE AND PIPERIDINE OREXIN RECEPTOR AGONISTS |
| EP4262788A4 (en) | 2020-12-16 | 2024-10-30 | Merck Sharp & Dohme LLC | OREXIN UREA RECEPTOR AGONISTS |
| JP2024510939A (en) | 2021-03-03 | 2024-03-12 | リサーチ トライアングル インスティテュート | Aryl sulfonamides as orexin receptor agonists |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| KR20240004802A (en) | 2021-05-03 | 2024-01-11 | 재즈 파마슈티칼즈 아일랜드 리미티드 | Orexin receptor agonists and uses thereof |
| TW202313598A (en) | 2021-05-26 | 2023-04-01 | 日商住友製藥股份有限公司 | Phenyl urea derivative |
| CA3224033A1 (en) | 2021-06-25 | 2022-12-29 | Davide MARINELLI | Sulfonamide orexin receptor agonists and uses thereof |
-
2021
- 2021-12-20 US US17/556,295 patent/US11760747B2/en active Active
- 2021-12-21 ES ES21854780T patent/ES3012114T3/en active Active
- 2021-12-21 AU AU2021409664A patent/AU2021409664A1/en active Pending
- 2021-12-21 CN CN202180080063.0A patent/CN116670124A/en active Pending
- 2021-12-21 CA CA3172862A patent/CA3172862A1/en active Pending
- 2021-12-21 JP JP2023534354A patent/JP2023554282A/en active Pending
- 2021-12-21 EP EP21854780.0A patent/EP4263506B1/en active Active
- 2021-12-21 WO PCT/US2021/064484 patent/WO2022140317A1/en active Application Filing
-
2023
- 2023-08-04 US US18/230,329 patent/US20240076283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4263506B1 (en) | 2025-02-05 |
| AU2021409664A9 (en) | 2024-10-24 |
| CA3172862A1 (en) | 2022-06-30 |
| US20220194926A1 (en) | 2022-06-23 |
| EP4263506A1 (en) | 2023-10-25 |
| WO2022140317A1 (en) | 2022-06-30 |
| ES3012114T3 (en) | 2025-04-08 |
| US11760747B2 (en) | 2023-09-19 |
| JP2023554282A (en) | 2023-12-27 |
| AU2021409664A1 (en) | 2023-05-25 |
| US20240076283A1 (en) | 2024-03-07 |
| CN116670124A (en) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4263506C0 (en) | SUBSTITUTED PIPERIDINE COMPOUNDS AND RELEVANT TREATMENT METHODS | |
| EP3594203A4 (en) | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | |
| EP3594202A4 (en) | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | |
| EP2237803A4 (en) | TREATMENT AND PROPHYLAXIS OF AMYLOIDOSE | |
| EP3582776A4 (en) | PIPERIDINE SUBSTITUTED MNK INHIBITORS AND RELATED PROCEDURES | |
| EP4324833A4 (en) | ALKYNYLPHENYLBENZAMIDE COMPOUND AND USE THEREOF | |
| EP4200301C0 (en) | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | |
| EP4178414A4 (en) | HEMOSTASIS METHODS AND DEVICES | |
| EP4294790A4 (en) | SMARCA DEGRADER AND USES THEREOF | |
| EP4171115A4 (en) | PROCEDURE PERFORMED BY USER DEVICE AND USER DEVICE | |
| EP4156847A4 (en) | PROCEDURE PERFORMED BY USER DEVICE AND USER DEVICE | |
| EP4291030A4 (en) | BIOCIDAL COMPOSITION AND METHOD | |
| EP4074183A4 (en) | CONCENTRATION METHOD AND EQUIPMENT | |
| DK4196479T3 (en) | SUBSTITUTED PYRIDOTRIAZINE COMPOUNDS AND USES THEREOF | |
| EP4112614A4 (en) | GLUTARIMIDE BACKGROUND-BASED COMPOUNDS AND USE THEREOF | |
| EP4225386C0 (en) | BIOACTIVABLE DEVICES AND RELATED METHODS | |
| EP3624783A4 (en) | TREATMENT AND PREVENTION OF MOTONEURON DISEASES USING NICOTINAMIDE RIBOSIDE | |
| EP3949802A4 (en) | DISINFECTANT AND TOOTHBRUSH | |
| EP3836068A4 (en) | INTERCHANGE DEVICE AND METHOD OF INTERCHANGE THEREWITH | |
| EP4244205A4 (en) | IRE1ALPHA INHIBITORS AND USES THEREOF | |
| EP4117655A4 (en) | TREATMENT PROCEDURES | |
| EP4185567A4 (en) | NAPHTHALENE MONOIMIDE COMPOUNDS AND METHODS THEREOF | |
| EP4130802A4 (en) | SCINTILLATOR PANEL AND SCINTILLATOR PANEL PRODUCTION METHOD | |
| DE112020004657A5 (en) | Treatment facility and treatment process | |
| EP4034240A4 (en) | TREATMENT OF TAUOPATHIES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230706 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ALKERMES, INC. |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40099265 Country of ref document: HK |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20240816 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602021025837 Country of ref document: DE |
|
| U01 | Request for unitary effect filed |
Effective date: 20250205 |
|
| U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI Effective date: 20250211 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 3012114 Country of ref document: ES Kind code of ref document: T3 Effective date: 20250408 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250505 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250205 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250605 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250505 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20250205 |